Cancer Research  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 44, 4285-4288, October 1, 1984]
© 1984 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Teicher, B. A.
Right arrow Articles by Rose, C. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Teicher, B. A.
Right arrow Articles by Rose, C. M.

Oxygen-carrying Perfluorochemical Emulsion as an Adjuvant to Radiation Therapy in Mice1

Beverly A. Teicher and Christopher M. Rose

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115 [B. A. T.], and St. Joseph Medical Center, Burbank, California 91505 [C. M. R.]

The potential of an oxygen-carrying perfluorochemical emulsion (PFCE) to enhance radiation damage in Lewis lung tumor growing in C57BL/6J x DBA/2J F1 mice was examined. PFCE and 95% (2:5% CO2 (carbogen) breathing caused a significant enhancement of single-fraction radiation damage measured by the growth delay assay. The dose-response effect of PFCE was very broad; doses as small as 0.5 ml/mouse were effective, and doses of 0.3 to 0.4 ml/mouse gave maximal enhancement. The peak dose-modifying factor was 2.8 ± 0.6 (S.E.). The addition of 0.3 ml of perfluorochemical-free annex solution with carbogen breathing produced a smaller enhancement in tumor growth delay; the dose-modifying factor was 1.5 ± 0.2. When the perfluorochemical treatment was added to a fractionated course of radiation therapy, a dose-modifying effect of 1.8 ± 0.3 was obtained. Oxygen-carrying PFCE may provide a nontoxic, clinically useful method of increasing the effectiveness of radiation therapy and of certain chemotherapeutic agents.

1 This research was supported by a grant from the Alpha Therapeutics Corp., Los Angeles, CA.

Received 2/27/84. Accepted 6/26/84.




This article has been cited by other articles:


Home page
Br. J. Radiol.Home page
T Wakasa, N Kawai, Y Yanagi, Y Hayase, and K Kishi
A study of hypoxic cell radiosensitizer applied to Ehrlich ascite tumour: a comparison of FC43 emulsion and pentoxyfilline
Br. J. Radiol., November 1, 2002; 75(899): 909 - 912.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. J. Koch, P. R. Oprysko, A. L. Shuman, W. T. Jenkins, G. Brandt, and S. M. Evans
Radiosensitization of Hypoxic Tumor Cells by Dodecafluoropentane: A Gas-Phase Perfluorochemical Emulsion
Cancer Res., July 1, 2002; 62(13): 3626 - 3629.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1984 by the American Association for Cancer Research.